Trial Details

Not Recruiting
Basic Information
Clinical ID c3138
Identifier ACTRN12613000751774
Trial Title In children with inflammatory bowel disease and iron deficiency, does intravenous iron therapy with Ferric Carboxymaltose signficantly improve cognitive function, quality of life and iron status.
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Paediatric Inflammatory Bowel Disease;Iron deficiency anaemia__;Iron deficiency without anaemia; Paediatric Inflammatory Bowel Disease Iron deficiency anaemia Iron deficiency without anaemia;Oral and Gastrointestinal - Inflammatory bowel disease
Interventions In Inflammatory bowel disease patients with iron deficiency, baseline iron status will be obtained, along with quality of life data (using IMPACT III questionnaire) and cognitive function (WISC). A single intravenous iron infusion with Ferric Carboxymaltose (15mg/kg up to a maxmum dose of 500mg, in 100mL N/Saline) will be administered, and 8 weeks following this iron status, quality of life and cognitive function will be obtained, and results compared. If iron deficiency is ongoing, a second infusion of Ferric Carboxymaltose will be administered.
Participant Information
Sponsor Gastroenterology Department, Royal Children's Hospital - Brisbane
City -
Country/Region Australia
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, CHILD, TEENAGER
Study Design
Study Type Interventional
Phase PHASE4
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -